Elliott, Alysha G. http://orcid.org/0000-0002-2983-0484
Huang, Johnny X. http://orcid.org/0000-0003-3595-208X
Neve, Søren
Zuegg, Johannes http://orcid.org/0000-0001-6240-6020
Edwards, Ingrid A. http://orcid.org/0000-0003-2903-0089
Cain, Amy K. http://orcid.org/0000-0002-4230-6572
Boinett, Christine J.
Barquist, Lars http://orcid.org/0000-0003-4732-2667
Lundberg, Carina Vingsbo
Steen, Jason
Butler, Mark S. http://orcid.org/0000-0001-6689-4236
Mobli, Mehdi http://orcid.org/0000-0003-2420-4262
Porter, Kaela M.
Blaskovich, Mark A. T. http://orcid.org/0000-0001-9447-2292
Lociuro, Sergio
Strandh, Magnus http://orcid.org/0000-0002-6878-1566
Cooper, Matthew A. http://orcid.org/0000-0003-3147-3460
Funding for this research was provided by:
Wellcome Trust (WT104797/Z/14/Z, WT104797/Z/14/Z, WT104797/Z/14/Z, WT098051, WT098051)
Adenium Biotech ApS
RCUK | Medical Research Council (G1100100/1, G1100100/1)
Department of Health | National Health and Medical Research Council (AP1106590, APP1059354)
Article History
Received: 12 February 2020
Accepted: 3 June 2020
First Online: 23 June 2020
Competing interests
: Matthew Cooper was Chair of the Scientific Advisory Board of Adenium Biotech from 2013 to 2019. He has no shareholding, current income, or any other interest in the company. Magnus Strandh was an employee of Adenium Biotech from 2017 to Jan 2020. Kaela Porter is an independent consultant operating as the Director, Preclinical Development of Adenium Biotech until Nov 2020. She has no current shareholding, income, or any other interest in the company. The remaining authors declare no competing interests.